Tumour heterogeneity in the clinic

By P. Bedard, A. Hansen, M. Ratain, L. Siu. Nature, 2013

1,164 citations recorded by the source corpus.

Recent therapeutic advances in oncology have been driven by the identification of tumour genotype variations between patients, called interpatient heterogeneity, that predict the response of patients to targeted treatments. Subpopulations of cancer cells with unique genomes in the same patient may exist across different geographical regions of a tumour or evolve over time, called intratumour heterogeneity. Sequencing technologies can be used to characterize intratumour heterogeneity at diagnosis, monitor clonal dynamics during treatment and identify the emergence of clinical resistance during disease progression. Genetic interpatient and intratumour heterogeneity can pose challenges for the design of clinical trials that use these data.

Subfields: Cancer Research, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/5a8cbc412e86c62764e0fe5d2474144ad1bc6e59

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

Citations in the corpus

Cancer Evolution: Mathematical Models and Computational Inference (2014, background): “Tumor heterogeneity and evolution as well as its clinical implications have been reviewed recently and extensively (de Bruin et al. 2013; Bedard et al. 2013; Klein 2013; Junttila and de Sauvage 2013; Burrell et al. 2013; Meacham and Morrison 2013; Almendro et al. 2013; Aparicio and Caldas 2013;…”
The MAPK pathway across different malignancies: A new perspective (2014, background): “The sensitivity of mutation detection depends on the dominant population of cells represented in the tumor sample that is tested and, thus, may not be illustrative of the tumor as a whole.(49) Discovery of specific oncogene mutations that activate the MAPK pathway has spurred the development of targ”
Genetics and biology of prostate cancer (2018, background): “Therapeutic advances in oncology have been shaped by a detailed catalog of genotypic variations between patients that informs responses to targeted treatments (Bedard et al. 2013).”
Roles of the immune system in cancer: from tumor initiation to metastatic progression (2018, background): “This poses an arduous clinical and technical challenge (Bedard et al. 2013; Kreso and Dick 2014).”
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma (2014, background): “Such intratumoral heterogeneity is increasingly appreciated as a determinant of treatment failure and disease recurrence (8).”